Reltecimod

Reltecimod is a CD28 antagonist investigated for the treatment of severe infections like necrotizing soft tissue infection. Its mechanism involves modulating T-cell co-stimulation, with research applications in immunology and sepsis studied in both in vitro and in vivo experimental models.